Global High-Purity PLGA Polymers for Long-Acting Injectables Market Growth 2026-2032
The global High-Purity PLGA Polymers for Long-Acting Injectables market size is predicted to grow from US$ 70.43 million in 2025 to US$ 168 million in 2032; it is expected to grow at a CAGR of 13.1% from 2026 to 2032.
In 2025, global sales volume of high-purity pharmaceutical-grade PLGA polymers for injectable long-acting formulations reached approximately 4.8 metric tons, with an average selling price of around US$15,000/kg and a market size of approximately US$72 million. High-purity pharmaceutical-grade PLGA polymers for injectable long-acting formulations refer to biodegradable pharmaceutical polymers synthesized by copolymerization of lactide and glycolide monomers, featuring good biocompatibility, controllable degradation and sustained drug release performance. These products are typically supplied in a range of lactide/glycolide ratios, molecular weights, inherent viscosities and end-group structures to support different release profiles and formulation stability requirements. This market focuses on high-purity pharmaceutical-grade PLGA polymers used in injectable controlled-release drug delivery systems, including long-acting injectables, sustained-release microspheres, in-situ forming depot systems, biodegradable drug-eluting implants and nanoparticle drug delivery systems.
On the demand side, long-acting drug delivery has become an important approach for pharmaceutical companies to improve patient adherence, extend product life cycles and differentiate formulations. Therapeutic areas such as central nervous system disorders, endocrinology, oncology supportive care, addiction treatment and chronic disease management all create demand for injectable controlled-release products. This is driving pharmaceutical companies and formulation CDMOs to procure high-purity, customizable and registration-ready PLGA materials. Compared with medical device-grade or research-grade PLGA, injectable pharmaceutical-grade PLGA requires stricter control over purity, molecular weight distribution, end-group chemistry, residual monomers, residual solvents and endotoxin levels, supporting its premium pricing and strong customer stickiness.
From a competitive perspective, the global high-end pharmaceutical-grade PLGA market remains concentrated among a limited number of suppliers in Europe, the United States and Japan. Companies such as Evonik, Corbion, Ashland, SEQENS and Mitsui Chemicals hold advantages in product portfolios, quality systems, regulatory support and customer validation. Chinese suppliers are entering the market through pharmaceutical excipient registration, injectable-grade product development and domestic substitution opportunities, but still need to strengthen their capabilities in batch consistency, scale-up quality control, international regulatory support and commercial customer validation. Future competition is expected to focus less on price and more on regulatory documentation, customization capability, supply reliability and deep integration with formulation development projects.
Overall, this is a high-quality niche market with strong research value and solid customer interest. The global market size is estimated at approximately US$72 million in 2025 and is expected to reach around US$82 million in 2026, with a projected CAGR of about 12.6% from 2026 to 2032. Given the long development cycle of long-acting injectables, the high cost of material replacement and the limited number of qualified suppliers, this market is not a large-volume commodity segment, but it is well suited as a focused research topic within high-end pharmaceutical excipients, complex formulation upstream materials and drug delivery materials.
LP Information, Inc. (LPI) ' newest research report, the ?High-Purity PLGA Polymers for Long-Acting Injectables Industry Forecast? looks at past sales and reviews total world High-Purity PLGA Polymers for Long-Acting Injectables sales in 2025, providing a comprehensive analysis by region and market sector of projected High-Purity PLGA Polymers for Long-Acting Injectables sales for 2026 through 2032. With High-Purity PLGA Polymers for Long-Acting Injectables sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world High-Purity PLGA Polymers for Long-Acting Injectables industry.
This Insight Report provides a comprehensive analysis of the global High-Purity PLGA Polymers for Long-Acting Injectables landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on High-Purity PLGA Polymers for Long-Acting Injectables portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global High-Purity PLGA Polymers for Long-Acting Injectables market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for High-Purity PLGA Polymers for Long-Acting Injectables and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global High-Purity PLGA Polymers for Long-Acting Injectables.
This report presents a comprehensive overview, market shares, and growth opportunities of High-Purity PLGA Polymers for Long-Acting Injectables market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global High-Purity PLGA Polymers for Long-Acting Injectables market?
What factors are driving High-Purity PLGA Polymers for Long-Acting Injectables market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do High-Purity PLGA Polymers for Long-Acting Injectables market opportunities vary by end market size?
How does High-Purity PLGA Polymers for Long-Acting Injectables break out by Type, by Application?
In 2025, global sales volume of high-purity pharmaceutical-grade PLGA polymers for injectable long-acting formulations reached approximately 4.8 metric tons, with an average selling price of around US$15,000/kg and a market size of approximately US$72 million. High-purity pharmaceutical-grade PLGA polymers for injectable long-acting formulations refer to biodegradable pharmaceutical polymers synthesized by copolymerization of lactide and glycolide monomers, featuring good biocompatibility, controllable degradation and sustained drug release performance. These products are typically supplied in a range of lactide/glycolide ratios, molecular weights, inherent viscosities and end-group structures to support different release profiles and formulation stability requirements. This market focuses on high-purity pharmaceutical-grade PLGA polymers used in injectable controlled-release drug delivery systems, including long-acting injectables, sustained-release microspheres, in-situ forming depot systems, biodegradable drug-eluting implants and nanoparticle drug delivery systems.
On the demand side, long-acting drug delivery has become an important approach for pharmaceutical companies to improve patient adherence, extend product life cycles and differentiate formulations. Therapeutic areas such as central nervous system disorders, endocrinology, oncology supportive care, addiction treatment and chronic disease management all create demand for injectable controlled-release products. This is driving pharmaceutical companies and formulation CDMOs to procure high-purity, customizable and registration-ready PLGA materials. Compared with medical device-grade or research-grade PLGA, injectable pharmaceutical-grade PLGA requires stricter control over purity, molecular weight distribution, end-group chemistry, residual monomers, residual solvents and endotoxin levels, supporting its premium pricing and strong customer stickiness.
From a competitive perspective, the global high-end pharmaceutical-grade PLGA market remains concentrated among a limited number of suppliers in Europe, the United States and Japan. Companies such as Evonik, Corbion, Ashland, SEQENS and Mitsui Chemicals hold advantages in product portfolios, quality systems, regulatory support and customer validation. Chinese suppliers are entering the market through pharmaceutical excipient registration, injectable-grade product development and domestic substitution opportunities, but still need to strengthen their capabilities in batch consistency, scale-up quality control, international regulatory support and commercial customer validation. Future competition is expected to focus less on price and more on regulatory documentation, customization capability, supply reliability and deep integration with formulation development projects.
Overall, this is a high-quality niche market with strong research value and solid customer interest. The global market size is estimated at approximately US$72 million in 2025 and is expected to reach around US$82 million in 2026, with a projected CAGR of about 12.6% from 2026 to 2032. Given the long development cycle of long-acting injectables, the high cost of material replacement and the limited number of qualified suppliers, this market is not a large-volume commodity segment, but it is well suited as a focused research topic within high-end pharmaceutical excipients, complex formulation upstream materials and drug delivery materials.
LP Information, Inc. (LPI) ' newest research report, the ?High-Purity PLGA Polymers for Long-Acting Injectables Industry Forecast? looks at past sales and reviews total world High-Purity PLGA Polymers for Long-Acting Injectables sales in 2025, providing a comprehensive analysis by region and market sector of projected High-Purity PLGA Polymers for Long-Acting Injectables sales for 2026 through 2032. With High-Purity PLGA Polymers for Long-Acting Injectables sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world High-Purity PLGA Polymers for Long-Acting Injectables industry.
This Insight Report provides a comprehensive analysis of the global High-Purity PLGA Polymers for Long-Acting Injectables landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on High-Purity PLGA Polymers for Long-Acting Injectables portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global High-Purity PLGA Polymers for Long-Acting Injectables market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for High-Purity PLGA Polymers for Long-Acting Injectables and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global High-Purity PLGA Polymers for Long-Acting Injectables.
This report presents a comprehensive overview, market shares, and growth opportunities of High-Purity PLGA Polymers for Long-Acting Injectables market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- PLGA 50:50
- PLGA 75:25
- PLGA 85:15
- Other Ratios and Customized PLGA
- Pharmaceutical Companies and Marketing Authorization Holders
- Formulation CDMOs and Drug Delivery Development Service Providers
- Research Institutions and Translational R&D Platforms
- Other End Users
- Sustained-release Microspheres
- In-situ Forming Depot Systems
- Biodegradable Drug-eluting Implants
- Nanoparticle Drug Delivery Systems
- Other Parenteral Controlled-release Applications
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Evonik Industries AG
- Corbion N.V.
- Ashland Inc.
- SEQENS
- Mitsui Chemicals, Inc.
- Nanjing Well Pharmaceutical Group Co., Ltd.
- Guangzhou DiQi Pharmaceuticals Co., Ltd.
- Nomisma Healthcare Pvt. Ltd.
- Zhejiang Langhua Pharmaceutical Co., Ltd.
- Hunan Er-Kang Pharmaceutical Co., Ltd.
- Shanghai Libaimei Biotechnology Co., Ltd.
- Zhejiang Bangyao Biomaterials Co., Ltd.
What is the 10-year outlook for the global High-Purity PLGA Polymers for Long-Acting Injectables market?
What factors are driving High-Purity PLGA Polymers for Long-Acting Injectables market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do High-Purity PLGA Polymers for Long-Acting Injectables market opportunities vary by end market size?
How does High-Purity PLGA Polymers for Long-Acting Injectables break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for High-Purity PLGA Polymers for Long-Acting Injectables by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for High-Purity PLGA Polymers for Long-Acting Injectables by Country/Region, 2021, 2025 & 2032
2.2 High-Purity PLGA Polymers for Long-Acting Injectables Segment by Type
2.2.1 PLGA 50:50
2.2.2 PLGA 75:25
2.2.3 PLGA 85:15
2.2.4 Other Ratios and Customized PLGA
2.2.5 High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type
2.2.5.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
2.2.5.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Type (2021-2026)
2.3 High-Purity PLGA Polymers for Long-Acting Injectables Segment by End User
2.3.1 Pharmaceutical Companies and Marketing Authorization Holders
2.3.2 Formulation CDMOs and Drug Delivery Development Service Providers
2.3.3 Research Institutions and Translational R&D Platforms
2.3.4 Other End Users
2.3.5 High-Purity PLGA Polymers for Long-Acting Injectables Sales by End User
2.3.5.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by End User (2021-2026)
2.3.5.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue and Market Share by End User (2021-2026)
2.3.5.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by End User (2021-2026)
2.4 High-Purity PLGA Polymers for Long-Acting Injectables Segment by Application
2.4.1 Sustained-release Microspheres
2.4.2 In-situ Forming Depot Systems
2.4.3 Biodegradable Drug-eluting Implants
2.4.4 Nanoparticle Drug Delivery Systems
2.4.5 Other Parenteral Controlled-release Applications
2.4.6 High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application
2.4.6.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Market Share by Application (2021-2026)
2.4.6.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue and Market Share by Application (2021-2026)
2.4.6.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Breakdown Data by Company
3.1.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales by Company (2021-2026)
3.1.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Company (2021-2026)
3.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue by Company (2021-2026)
3.2.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Company (2021-2026)
3.2.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Company (2021-2026)
3.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Company
3.4 Key Manufacturers High-Purity PLGA Polymers for Long-Acting Injectables Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers High-Purity PLGA Polymers for Long-Acting Injectables Product Location Distribution
3.4.2 Players High-Purity PLGA Polymers for Long-Acting Injectables Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIGH-PURITY PLGA POLYMERS FOR LONG-ACTING INJECTABLES BY GEOGRAPHIC REGION
4.1 World Historic High-Purity PLGA Polymers for Long-Acting Injectables Market Size by Geographic Region (2021-2026)
4.1.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales by Geographic Region (2021-2026)
4.1.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic High-Purity PLGA Polymers for Long-Acting Injectables Market Size by Country/Region (2021-2026)
4.2.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales by Country/Region (2021-2026)
4.2.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue by Country/Region (2021-2026)
4.3 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth
4.4 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth
4.5 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth
4.6 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth
5 AMERICAS
5.1 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country
5.1.1 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026)
5.1.2 Americas High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026)
5.2 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026)
5.3 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region
6.1.1 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region (2021-2026)
6.1.2 APAC High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Region (2021-2026)
6.2 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026)
6.3 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe High-Purity PLGA Polymers for Long-Acting Injectables by Country
7.1.1 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026)
7.1.2 Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026)
7.2 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026)
7.3 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables by Country
8.1.1 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026)
8.1.2 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026)
8.2 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026)
8.3 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of High-Purity PLGA Polymers for Long-Acting Injectables
10.3 Manufacturing Process Analysis of High-Purity PLGA Polymers for Long-Acting Injectables
10.4 Industry Chain Structure of High-Purity PLGA Polymers for Long-Acting Injectables
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 High-Purity PLGA Polymers for Long-Acting Injectables Distributors
11.3 High-Purity PLGA Polymers for Long-Acting Injectables Customer
12 WORLD FORECAST REVIEW FOR HIGH-PURITY PLGA POLYMERS FOR LONG-ACTING INJECTABLES BY GEOGRAPHIC REGION
12.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Market Size Forecast by Region
12.1.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Forecast by Region (2027-2032)
12.1.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global High-Purity PLGA Polymers for Long-Acting Injectables Forecast by Type (2027-2032)
12.7 Global High-Purity PLGA Polymers for Long-Acting Injectables Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Evonik Industries AG
13.1.1 Evonik Industries AG Company Information
13.1.2 Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.1.3 Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Evonik Industries AG Main Business Overview
13.1.5 Evonik Industries AG Latest Developments
13.2 Corbion N.V.
13.2.1 Corbion N.V. Company Information
13.2.2 Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.2.3 Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Corbion N.V. Main Business Overview
13.2.5 Corbion N.V. Latest Developments
13.3 Ashland Inc.
13.3.1 Ashland Inc. Company Information
13.3.2 Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.3.3 Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Ashland Inc. Main Business Overview
13.3.5 Ashland Inc. Latest Developments
13.4 SEQENS
13.4.1 SEQENS Company Information
13.4.2 SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.4.3 SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 SEQENS Main Business Overview
13.4.5 SEQENS Latest Developments
13.5 Mitsui Chemicals, Inc.
13.5.1 Mitsui Chemicals, Inc. Company Information
13.5.2 Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.5.3 Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Mitsui Chemicals, Inc. Main Business Overview
13.5.5 Mitsui Chemicals, Inc. Latest Developments
13.6 Nanjing Well Pharmaceutical Group Co., Ltd.
13.6.1 Nanjing Well Pharmaceutical Group Co., Ltd. Company Information
13.6.2 Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.6.3 Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Nanjing Well Pharmaceutical Group Co., Ltd. Main Business Overview
13.6.5 Nanjing Well Pharmaceutical Group Co., Ltd. Latest Developments
13.7 Guangzhou DiQi Pharmaceuticals Co., Ltd.
13.7.1 Guangzhou DiQi Pharmaceuticals Co., Ltd. Company Information
13.7.2 Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.7.3 Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Guangzhou DiQi Pharmaceuticals Co., Ltd. Main Business Overview
13.7.5 Guangzhou DiQi Pharmaceuticals Co., Ltd. Latest Developments
13.8 Nomisma Healthcare Pvt. Ltd.
13.8.1 Nomisma Healthcare Pvt. Ltd. Company Information
13.8.2 Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.8.3 Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nomisma Healthcare Pvt. Ltd. Main Business Overview
13.8.5 Nomisma Healthcare Pvt. Ltd. Latest Developments
13.9 Zhejiang Langhua Pharmaceutical Co., Ltd.
13.9.1 Zhejiang Langhua Pharmaceutical Co., Ltd. Company Information
13.9.2 Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.9.3 Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Zhejiang Langhua Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Zhejiang Langhua Pharmaceutical Co., Ltd. Latest Developments
13.10 Hunan Er-Kang Pharmaceutical Co., Ltd.
13.10.1 Hunan Er-Kang Pharmaceutical Co., Ltd. Company Information
13.10.2 Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.10.3 Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Hunan Er-Kang Pharmaceutical Co., Ltd. Main Business Overview
13.10.5 Hunan Er-Kang Pharmaceutical Co., Ltd. Latest Developments
13.11 Shanghai Libaimei Biotechnology Co., Ltd.
13.11.1 Shanghai Libaimei Biotechnology Co., Ltd. Company Information
13.11.2 Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.11.3 Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Shanghai Libaimei Biotechnology Co., Ltd. Main Business Overview
13.11.5 Shanghai Libaimei Biotechnology Co., Ltd. Latest Developments
13.12 Zhejiang Bangyao Biomaterials Co., Ltd.
13.12.1 Zhejiang Bangyao Biomaterials Co., Ltd. Company Information
13.12.2 Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.12.3 Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Zhejiang Bangyao Biomaterials Co., Ltd. Main Business Overview
13.12.5 Zhejiang Bangyao Biomaterials Co., Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for High-Purity PLGA Polymers for Long-Acting Injectables by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for High-Purity PLGA Polymers for Long-Acting Injectables by Country/Region, 2021, 2025 & 2032
2.2 High-Purity PLGA Polymers for Long-Acting Injectables Segment by Type
2.2.1 PLGA 50:50
2.2.2 PLGA 75:25
2.2.3 PLGA 85:15
2.2.4 Other Ratios and Customized PLGA
2.2.5 High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type
2.2.5.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
2.2.5.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Type (2021-2026)
2.3 High-Purity PLGA Polymers for Long-Acting Injectables Segment by End User
2.3.1 Pharmaceutical Companies and Marketing Authorization Holders
2.3.2 Formulation CDMOs and Drug Delivery Development Service Providers
2.3.3 Research Institutions and Translational R&D Platforms
2.3.4 Other End Users
2.3.5 High-Purity PLGA Polymers for Long-Acting Injectables Sales by End User
2.3.5.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by End User (2021-2026)
2.3.5.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue and Market Share by End User (2021-2026)
2.3.5.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by End User (2021-2026)
2.4 High-Purity PLGA Polymers for Long-Acting Injectables Segment by Application
2.4.1 Sustained-release Microspheres
2.4.2 In-situ Forming Depot Systems
2.4.3 Biodegradable Drug-eluting Implants
2.4.4 Nanoparticle Drug Delivery Systems
2.4.5 Other Parenteral Controlled-release Applications
2.4.6 High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application
2.4.6.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Market Share by Application (2021-2026)
2.4.6.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue and Market Share by Application (2021-2026)
2.4.6.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Breakdown Data by Company
3.1.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales by Company (2021-2026)
3.1.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Company (2021-2026)
3.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue by Company (2021-2026)
3.2.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Company (2021-2026)
3.2.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Company (2021-2026)
3.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Company
3.4 Key Manufacturers High-Purity PLGA Polymers for Long-Acting Injectables Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers High-Purity PLGA Polymers for Long-Acting Injectables Product Location Distribution
3.4.2 Players High-Purity PLGA Polymers for Long-Acting Injectables Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIGH-PURITY PLGA POLYMERS FOR LONG-ACTING INJECTABLES BY GEOGRAPHIC REGION
4.1 World Historic High-Purity PLGA Polymers for Long-Acting Injectables Market Size by Geographic Region (2021-2026)
4.1.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales by Geographic Region (2021-2026)
4.1.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic High-Purity PLGA Polymers for Long-Acting Injectables Market Size by Country/Region (2021-2026)
4.2.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales by Country/Region (2021-2026)
4.2.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue by Country/Region (2021-2026)
4.3 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth
4.4 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth
4.5 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth
4.6 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth
5 AMERICAS
5.1 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country
5.1.1 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026)
5.1.2 Americas High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026)
5.2 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026)
5.3 Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region
6.1.1 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region (2021-2026)
6.1.2 APAC High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Region (2021-2026)
6.2 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026)
6.3 APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe High-Purity PLGA Polymers for Long-Acting Injectables by Country
7.1.1 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026)
7.1.2 Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026)
7.2 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026)
7.3 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables by Country
8.1.1 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026)
8.1.2 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026)
8.2 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026)
8.3 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of High-Purity PLGA Polymers for Long-Acting Injectables
10.3 Manufacturing Process Analysis of High-Purity PLGA Polymers for Long-Acting Injectables
10.4 Industry Chain Structure of High-Purity PLGA Polymers for Long-Acting Injectables
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 High-Purity PLGA Polymers for Long-Acting Injectables Distributors
11.3 High-Purity PLGA Polymers for Long-Acting Injectables Customer
12 WORLD FORECAST REVIEW FOR HIGH-PURITY PLGA POLYMERS FOR LONG-ACTING INJECTABLES BY GEOGRAPHIC REGION
12.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Market Size Forecast by Region
12.1.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Forecast by Region (2027-2032)
12.1.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global High-Purity PLGA Polymers for Long-Acting Injectables Forecast by Type (2027-2032)
12.7 Global High-Purity PLGA Polymers for Long-Acting Injectables Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Evonik Industries AG
13.1.1 Evonik Industries AG Company Information
13.1.2 Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.1.3 Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Evonik Industries AG Main Business Overview
13.1.5 Evonik Industries AG Latest Developments
13.2 Corbion N.V.
13.2.1 Corbion N.V. Company Information
13.2.2 Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.2.3 Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Corbion N.V. Main Business Overview
13.2.5 Corbion N.V. Latest Developments
13.3 Ashland Inc.
13.3.1 Ashland Inc. Company Information
13.3.2 Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.3.3 Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Ashland Inc. Main Business Overview
13.3.5 Ashland Inc. Latest Developments
13.4 SEQENS
13.4.1 SEQENS Company Information
13.4.2 SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.4.3 SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 SEQENS Main Business Overview
13.4.5 SEQENS Latest Developments
13.5 Mitsui Chemicals, Inc.
13.5.1 Mitsui Chemicals, Inc. Company Information
13.5.2 Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.5.3 Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Mitsui Chemicals, Inc. Main Business Overview
13.5.5 Mitsui Chemicals, Inc. Latest Developments
13.6 Nanjing Well Pharmaceutical Group Co., Ltd.
13.6.1 Nanjing Well Pharmaceutical Group Co., Ltd. Company Information
13.6.2 Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.6.3 Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Nanjing Well Pharmaceutical Group Co., Ltd. Main Business Overview
13.6.5 Nanjing Well Pharmaceutical Group Co., Ltd. Latest Developments
13.7 Guangzhou DiQi Pharmaceuticals Co., Ltd.
13.7.1 Guangzhou DiQi Pharmaceuticals Co., Ltd. Company Information
13.7.2 Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.7.3 Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Guangzhou DiQi Pharmaceuticals Co., Ltd. Main Business Overview
13.7.5 Guangzhou DiQi Pharmaceuticals Co., Ltd. Latest Developments
13.8 Nomisma Healthcare Pvt. Ltd.
13.8.1 Nomisma Healthcare Pvt. Ltd. Company Information
13.8.2 Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.8.3 Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Nomisma Healthcare Pvt. Ltd. Main Business Overview
13.8.5 Nomisma Healthcare Pvt. Ltd. Latest Developments
13.9 Zhejiang Langhua Pharmaceutical Co., Ltd.
13.9.1 Zhejiang Langhua Pharmaceutical Co., Ltd. Company Information
13.9.2 Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.9.3 Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Zhejiang Langhua Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Zhejiang Langhua Pharmaceutical Co., Ltd. Latest Developments
13.10 Hunan Er-Kang Pharmaceutical Co., Ltd.
13.10.1 Hunan Er-Kang Pharmaceutical Co., Ltd. Company Information
13.10.2 Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.10.3 Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Hunan Er-Kang Pharmaceutical Co., Ltd. Main Business Overview
13.10.5 Hunan Er-Kang Pharmaceutical Co., Ltd. Latest Developments
13.11 Shanghai Libaimei Biotechnology Co., Ltd.
13.11.1 Shanghai Libaimei Biotechnology Co., Ltd. Company Information
13.11.2 Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.11.3 Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Shanghai Libaimei Biotechnology Co., Ltd. Main Business Overview
13.11.5 Shanghai Libaimei Biotechnology Co., Ltd. Latest Developments
13.12 Zhejiang Bangyao Biomaterials Co., Ltd.
13.12.1 Zhejiang Bangyao Biomaterials Co., Ltd. Company Information
13.12.2 Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
13.12.3 Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Zhejiang Bangyao Biomaterials Co., Ltd. Main Business Overview
13.12.5 Zhejiang Bangyao Biomaterials Co., Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of PLGA 50:50
Table 4. Major Players of PLGA 75:25
Table 5. Major Players of PLGA 85:15
Table 6. Major Players of Other Ratios and Customized PLGA
Table 7. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 8. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Table 9. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Type (2021-2026) & ($ million)
Table 10. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Type (2021-2026)
Table 11. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Type (2021-2026) & (US$/kg)
Table 12. Major Players of Pharmaceutical Companies and Marketing Authorization Holders
Table 13. Major Players of Formulation CDMOs and Drug Delivery Development Service Providers
Table 14. Major Players of Research Institutions and Translational R&D Platforms
Table 15. Major Players of Other End Users
Table 16. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by End User (2021-2026) & (Tons)
Table 17. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by End User (2021-2026)
Table 18. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by End User (2021-2026) & ($ million)
Table 19. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by End User (2021-2026)
Table 20. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by End User (2021-2026) & (US$/kg)
Table 21. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale by Application (2021-2026) & (Tons)
Table 22. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Market Share by Application (2021-2026)
Table 23. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Application (2021-2026) & ($ million)
Table 24. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Application (2021-2026)
Table 25. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Application (2021-2026) & (US$/kg)
Table 26. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Company (2021-2026) & (Tons)
Table 27. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Company (2021-2026)
Table 28. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Company (2021-2026) & ($ millions)
Table 29. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Company (2021-2026)
Table 30. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Company (2021-2026) & (US$/kg)
Table 31. Key Manufacturers High-Purity PLGA Polymers for Long-Acting Injectables Producing Area Distribution and Sales Area
Table 32. Players High-Purity PLGA Polymers for Long-Acting Injectables Products Offered
Table 33. High-Purity PLGA Polymers for Long-Acting Injectables Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 34. New Products and Potential Entrants
Table 35. Market M&A Activity & Strategy
Table 36. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Geographic Region (2021-2026) & (Tons)
Table 37. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share Geographic Region (2021-2026)
Table 38. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Geographic Region (2021-2026) & ($ millions)
Table 39. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Geographic Region (2021-2026)
Table 40. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country/Region (2021-2026) & (Tons)
Table 41. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country/Region (2021-2026)
Table 42. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country/Region (2021-2026) & ($ millions)
Table 43. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Country/Region (2021-2026)
Table 44. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026) & (Tons)
Table 45. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country (2021-2026)
Table 46. Americas High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026) & ($ millions)
Table 47. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 48. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026) & (Tons)
Table 49. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region (2021-2026) & (Tons)
Table 50. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Region (2021-2026)
Table 51. APAC High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Region (2021-2026) & ($ millions)
Table 52. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 53. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026) & (Tons)
Table 54. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026) & (Tons)
Table 55. Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026) & ($ millions)
Table 56. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 57. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026) & (Tons)
Table 58. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026) & (Tons)
Table 59. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Country (2021-2026)
Table 60. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 61. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026) & (Tons)
Table 62. Key Market Drivers & Growth Opportunities of High-Purity PLGA Polymers for Long-Acting Injectables
Table 63. Key Market Challenges & Risks of High-Purity PLGA Polymers for Long-Acting Injectables
Table 64. Key Industry Trends of High-Purity PLGA Polymers for Long-Acting Injectables
Table 65. High-Purity PLGA Polymers for Long-Acting Injectables Raw Material
Table 66. Key Suppliers of Raw Materials
Table 67. High-Purity PLGA Polymers for Long-Acting Injectables Distributors List
Table 68. High-Purity PLGA Polymers for Long-Acting Injectables Customer List
Table 69. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Region (2027-2032) & (Tons)
Table 70. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Region (2027-2032) & ($ millions)
Table 71. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Country (2027-2032) & (Tons)
Table 72. Americas High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Region (2027-2032) & (Tons)
Table 74. APAC High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Country (2027-2032) & (Tons)
Table 76. Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Country (2027-2032) & (Tons)
Table 78. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Type (2027-2032) & (Tons)
Table 80. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Type (2027-2032) & ($ millions)
Table 81. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Application (2027-2032) & (Tons)
Table 82. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Application (2027-2032) & ($ millions)
Table 83. Evonik Industries AG Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 84. Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 85. Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 86. Evonik Industries AG Main Business
Table 87. Evonik Industries AG Latest Developments
Table 88. Corbion N.V. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 89. Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 90. Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 91. Corbion N.V. Main Business
Table 92. Corbion N.V. Latest Developments
Table 93. Ashland Inc. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 94. Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 95. Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 96. Ashland Inc. Main Business
Table 97. Ashland Inc. Latest Developments
Table 98. SEQENS Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 99. SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 100. SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 101. SEQENS Main Business
Table 102. SEQENS Latest Developments
Table 103. Mitsui Chemicals, Inc. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 104. Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 105. Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 106. Mitsui Chemicals, Inc. Main Business
Table 107. Mitsui Chemicals, Inc. Latest Developments
Table 108. Nanjing Well Pharmaceutical Group Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 109. Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 110. Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 111. Nanjing Well Pharmaceutical Group Co., Ltd. Main Business
Table 112. Nanjing Well Pharmaceutical Group Co., Ltd. Latest Developments
Table 113. Guangzhou DiQi Pharmaceuticals Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 114. Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 115. Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 116. Guangzhou DiQi Pharmaceuticals Co., Ltd. Main Business
Table 117. Guangzhou DiQi Pharmaceuticals Co., Ltd. Latest Developments
Table 118. Nomisma Healthcare Pvt. Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 119. Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 120. Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 121. Nomisma Healthcare Pvt. Ltd. Main Business
Table 122. Nomisma Healthcare Pvt. Ltd. Latest Developments
Table 123. Zhejiang Langhua Pharmaceutical Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 124. Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 125. Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 126. Zhejiang Langhua Pharmaceutical Co., Ltd. Main Business
Table 127. Zhejiang Langhua Pharmaceutical Co., Ltd. Latest Developments
Table 128. Hunan Er-Kang Pharmaceutical Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 129. Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 130. Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 131. Hunan Er-Kang Pharmaceutical Co., Ltd. Main Business
Table 132. Hunan Er-Kang Pharmaceutical Co., Ltd. Latest Developments
Table 133. Shanghai Libaimei Biotechnology Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 134. Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 135. Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 136. Shanghai Libaimei Biotechnology Co., Ltd. Main Business
Table 137. Shanghai Libaimei Biotechnology Co., Ltd. Latest Developments
Table 138. Zhejiang Bangyao Biomaterials Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 139. Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 140. Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 141. Zhejiang Bangyao Biomaterials Co., Ltd. Main Business
Table 142. Zhejiang Bangyao Biomaterials Co., Ltd. Latest Developments
Table 1. High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. High-Purity PLGA Polymers for Long-Acting Injectables Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of PLGA 50:50
Table 4. Major Players of PLGA 75:25
Table 5. Major Players of PLGA 85:15
Table 6. Major Players of Other Ratios and Customized PLGA
Table 7. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 8. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Table 9. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Type (2021-2026) & ($ million)
Table 10. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Type (2021-2026)
Table 11. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Type (2021-2026) & (US$/kg)
Table 12. Major Players of Pharmaceutical Companies and Marketing Authorization Holders
Table 13. Major Players of Formulation CDMOs and Drug Delivery Development Service Providers
Table 14. Major Players of Research Institutions and Translational R&D Platforms
Table 15. Major Players of Other End Users
Table 16. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by End User (2021-2026) & (Tons)
Table 17. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by End User (2021-2026)
Table 18. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by End User (2021-2026) & ($ million)
Table 19. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by End User (2021-2026)
Table 20. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by End User (2021-2026) & (US$/kg)
Table 21. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale by Application (2021-2026) & (Tons)
Table 22. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Market Share by Application (2021-2026)
Table 23. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Application (2021-2026) & ($ million)
Table 24. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Application (2021-2026)
Table 25. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Application (2021-2026) & (US$/kg)
Table 26. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Company (2021-2026) & (Tons)
Table 27. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Company (2021-2026)
Table 28. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Company (2021-2026) & ($ millions)
Table 29. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Company (2021-2026)
Table 30. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Price by Company (2021-2026) & (US$/kg)
Table 31. Key Manufacturers High-Purity PLGA Polymers for Long-Acting Injectables Producing Area Distribution and Sales Area
Table 32. Players High-Purity PLGA Polymers for Long-Acting Injectables Products Offered
Table 33. High-Purity PLGA Polymers for Long-Acting Injectables Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 34. New Products and Potential Entrants
Table 35. Market M&A Activity & Strategy
Table 36. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Geographic Region (2021-2026) & (Tons)
Table 37. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share Geographic Region (2021-2026)
Table 38. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Geographic Region (2021-2026) & ($ millions)
Table 39. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Geographic Region (2021-2026)
Table 40. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country/Region (2021-2026) & (Tons)
Table 41. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country/Region (2021-2026)
Table 42. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country/Region (2021-2026) & ($ millions)
Table 43. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Country/Region (2021-2026)
Table 44. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026) & (Tons)
Table 45. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country (2021-2026)
Table 46. Americas High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026) & ($ millions)
Table 47. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 48. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026) & (Tons)
Table 49. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region (2021-2026) & (Tons)
Table 50. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Region (2021-2026)
Table 51. APAC High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Region (2021-2026) & ($ millions)
Table 52. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 53. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026) & (Tons)
Table 54. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026) & (Tons)
Table 55. Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Country (2021-2026) & ($ millions)
Table 56. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 57. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026) & (Tons)
Table 58. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026) & (Tons)
Table 59. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Country (2021-2026)
Table 60. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Type (2021-2026) & (Tons)
Table 61. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales by Application (2021-2026) & (Tons)
Table 62. Key Market Drivers & Growth Opportunities of High-Purity PLGA Polymers for Long-Acting Injectables
Table 63. Key Market Challenges & Risks of High-Purity PLGA Polymers for Long-Acting Injectables
Table 64. Key Industry Trends of High-Purity PLGA Polymers for Long-Acting Injectables
Table 65. High-Purity PLGA Polymers for Long-Acting Injectables Raw Material
Table 66. Key Suppliers of Raw Materials
Table 67. High-Purity PLGA Polymers for Long-Acting Injectables Distributors List
Table 68. High-Purity PLGA Polymers for Long-Acting Injectables Customer List
Table 69. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Region (2027-2032) & (Tons)
Table 70. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Region (2027-2032) & ($ millions)
Table 71. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Country (2027-2032) & (Tons)
Table 72. Americas High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 73. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Region (2027-2032) & (Tons)
Table 74. APAC High-Purity PLGA Polymers for Long-Acting Injectables Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Country (2027-2032) & (Tons)
Table 76. Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Country (2027-2032) & (Tons)
Table 78. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Type (2027-2032) & (Tons)
Table 80. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Type (2027-2032) & ($ millions)
Table 81. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Forecast by Application (2027-2032) & (Tons)
Table 82. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Forecast by Application (2027-2032) & ($ millions)
Table 83. Evonik Industries AG Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 84. Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 85. Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 86. Evonik Industries AG Main Business
Table 87. Evonik Industries AG Latest Developments
Table 88. Corbion N.V. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 89. Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 90. Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 91. Corbion N.V. Main Business
Table 92. Corbion N.V. Latest Developments
Table 93. Ashland Inc. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 94. Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 95. Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 96. Ashland Inc. Main Business
Table 97. Ashland Inc. Latest Developments
Table 98. SEQENS Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 99. SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 100. SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 101. SEQENS Main Business
Table 102. SEQENS Latest Developments
Table 103. Mitsui Chemicals, Inc. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 104. Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 105. Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 106. Mitsui Chemicals, Inc. Main Business
Table 107. Mitsui Chemicals, Inc. Latest Developments
Table 108. Nanjing Well Pharmaceutical Group Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 109. Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 110. Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 111. Nanjing Well Pharmaceutical Group Co., Ltd. Main Business
Table 112. Nanjing Well Pharmaceutical Group Co., Ltd. Latest Developments
Table 113. Guangzhou DiQi Pharmaceuticals Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 114. Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 115. Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 116. Guangzhou DiQi Pharmaceuticals Co., Ltd. Main Business
Table 117. Guangzhou DiQi Pharmaceuticals Co., Ltd. Latest Developments
Table 118. Nomisma Healthcare Pvt. Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 119. Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 120. Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 121. Nomisma Healthcare Pvt. Ltd. Main Business
Table 122. Nomisma Healthcare Pvt. Ltd. Latest Developments
Table 123. Zhejiang Langhua Pharmaceutical Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 124. Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 125. Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 126. Zhejiang Langhua Pharmaceutical Co., Ltd. Main Business
Table 127. Zhejiang Langhua Pharmaceutical Co., Ltd. Latest Developments
Table 128. Hunan Er-Kang Pharmaceutical Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 129. Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 130. Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 131. Hunan Er-Kang Pharmaceutical Co., Ltd. Main Business
Table 132. Hunan Er-Kang Pharmaceutical Co., Ltd. Latest Developments
Table 133. Shanghai Libaimei Biotechnology Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 134. Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 135. Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 136. Shanghai Libaimei Biotechnology Co., Ltd. Main Business
Table 137. Shanghai Libaimei Biotechnology Co., Ltd. Latest Developments
Table 138. Zhejiang Bangyao Biomaterials Co., Ltd. Basic Information, High-Purity PLGA Polymers for Long-Acting Injectables Manufacturing Base, Sales Area and Its Competitors
Table 139. Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolios and Specifications
Table 140. Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (Tons), Revenue ($ Million), Price (US$/kg) and Gross Margin (2021-2026)
Table 141. Zhejiang Bangyao Biomaterials Co., Ltd. Main Business
Table 142. Zhejiang Bangyao Biomaterials Co., Ltd. Latest Developments
LIST OF FIGURES
Figure 1. Picture of High-Purity PLGA Polymers for Long-Acting Injectables
Figure 2. High-Purity PLGA Polymers for Long-Acting Injectables Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth Rate 2021-2032 (Tons)
Figure 7. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. High-Purity PLGA Polymers for Long-Acting Injectables Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country/Region (2025)
Figure 10. High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of PLGA 50:50
Figure 12. Product Picture of PLGA 75:25
Figure 13. Product Picture of PLGA 85:15
Figure 14. Product Picture of Other Ratios and Customized PLGA
Figure 15. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type in 2026
Figure 16. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Pharmaceutical Companies and Marketing Authorization Holders
Figure 18. Product Picture of Formulation CDMOs and Drug Delivery Development Service Providers
Figure 19. Product Picture of Research Institutions and Translational R&D Platforms
Figure 20. Product Picture of Other End Users
Figure 21. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by End User in 2026
Figure 22. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by End User (2021-2026)
Figure 23. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in Sustained-release Microspheres
Figure 24. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: Sustained-release Microspheres (2021-2026) & (Tons)
Figure 25. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in In-situ Forming Depot Systems
Figure 26. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: In-situ Forming Depot Systems (2021-2026) & (Tons)
Figure 27. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in Biodegradable Drug-eluting Implants
Figure 28. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: Biodegradable Drug-eluting Implants (2021-2026) & (Tons)
Figure 29. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in Nanoparticle Drug Delivery Systems
Figure 30. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: Nanoparticle Drug Delivery Systems (2021-2026) & (Tons)
Figure 31. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in Other Parenteral Controlled-release Applications
Figure 32. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: Other Parenteral Controlled-release Applications (2021-2026) & (Tons)
Figure 33. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Market Share by Application (2025)
Figure 34. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Application in 2025
Figure 35. High-Purity PLGA Polymers for Long-Acting Injectables Sales by Company in 2025 (Tons)
Figure 36. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Company in 2025
Figure 37. High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Company in 2025 ($ millions)
Figure 38. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Company in 2025
Figure 39. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Geographic Region (2021-2026)
Figure 40. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Geographic Region in 2025
Figure 41. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales 2021-2026 (Tons)
Figure 42. Americas High-Purity PLGA Polymers for Long-Acting Injectables Revenue 2021-2026 ($ millions)
Figure 43. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales 2021-2026 (Tons)
Figure 44. APAC High-Purity PLGA Polymers for Long-Acting Injectables Revenue 2021-2026 ($ millions)
Figure 45. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales 2021-2026 (Tons)
Figure 46. Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue 2021-2026 ($ millions)
Figure 47. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales 2021-2026 (Tons)
Figure 48. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue 2021-2026 ($ millions)
Figure 49. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country in 2025
Figure 50. Americas High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Country (2021-2026)
Figure 51. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Figure 52. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Application (2021-2026)
Figure 53. United States High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 54. Canada High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 55. Mexico High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 56. Brazil High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 57. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Region in 2025
Figure 58. APAC High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Region (2021-2026)
Figure 59. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Figure 60. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Application (2021-2026)
Figure 61. China High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 62. Japan High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 63. South Korea High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 64. Southeast Asia High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 65. India High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 66. Australia High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 67. China Taiwan High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 68. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country in 2025
Figure 69. Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Country (2021-2026)
Figure 70. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Figure 71. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Application (2021-2026)
Figure 72. Germany High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 73. France High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 74. UK High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 75. Italy High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 76. Russia High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 77. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country (2021-2026)
Figure 78. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Figure 79. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Application (2021-2026)
Figure 80. Egypt High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 81. South Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 82. Israel High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 83. Turkey High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 84. GCC Countries High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 85. Manufacturing Cost Structure Analysis of High-Purity PLGA Polymers for Long-Acting Injectables in 2026
Figure 86. Manufacturing Process Analysis of High-Purity PLGA Polymers for Long-Acting Injectables
Figure 87. Industry Chain Structure of High-Purity PLGA Polymers for Long-Acting Injectables
Figure 88. Channels of Distribution
Figure 89. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Forecast by Region (2027-2032)
Figure 90. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share Forecast by Region (2027-2032)
Figure 91. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share Forecast by Type (2027-2032)
Figure 92. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share Forecast by Type (2027-2032)
Figure 93. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share Forecast by Application (2027-2032)
Figure 94. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of High-Purity PLGA Polymers for Long-Acting Injectables
Figure 2. High-Purity PLGA Polymers for Long-Acting Injectables Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Growth Rate 2021-2032 (Tons)
Figure 7. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. High-Purity PLGA Polymers for Long-Acting Injectables Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country/Region (2025)
Figure 10. High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of PLGA 50:50
Figure 12. Product Picture of PLGA 75:25
Figure 13. Product Picture of PLGA 85:15
Figure 14. Product Picture of Other Ratios and Customized PLGA
Figure 15. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type in 2026
Figure 16. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Pharmaceutical Companies and Marketing Authorization Holders
Figure 18. Product Picture of Formulation CDMOs and Drug Delivery Development Service Providers
Figure 19. Product Picture of Research Institutions and Translational R&D Platforms
Figure 20. Product Picture of Other End Users
Figure 21. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by End User in 2026
Figure 22. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by End User (2021-2026)
Figure 23. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in Sustained-release Microspheres
Figure 24. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: Sustained-release Microspheres (2021-2026) & (Tons)
Figure 25. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in In-situ Forming Depot Systems
Figure 26. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: In-situ Forming Depot Systems (2021-2026) & (Tons)
Figure 27. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in Biodegradable Drug-eluting Implants
Figure 28. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: Biodegradable Drug-eluting Implants (2021-2026) & (Tons)
Figure 29. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in Nanoparticle Drug Delivery Systems
Figure 30. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: Nanoparticle Drug Delivery Systems (2021-2026) & (Tons)
Figure 31. High-Purity PLGA Polymers for Long-Acting Injectables Consumed in Other Parenteral Controlled-release Applications
Figure 32. Global High-Purity PLGA Polymers for Long-Acting Injectables Market: Other Parenteral Controlled-release Applications (2021-2026) & (Tons)
Figure 33. Global High-Purity PLGA Polymers for Long-Acting Injectables Sale Market Share by Application (2025)
Figure 34. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Application in 2025
Figure 35. High-Purity PLGA Polymers for Long-Acting Injectables Sales by Company in 2025 (Tons)
Figure 36. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Company in 2025
Figure 37. High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Company in 2025 ($ millions)
Figure 38. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Company in 2025
Figure 39. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Geographic Region (2021-2026)
Figure 40. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Geographic Region in 2025
Figure 41. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales 2021-2026 (Tons)
Figure 42. Americas High-Purity PLGA Polymers for Long-Acting Injectables Revenue 2021-2026 ($ millions)
Figure 43. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales 2021-2026 (Tons)
Figure 44. APAC High-Purity PLGA Polymers for Long-Acting Injectables Revenue 2021-2026 ($ millions)
Figure 45. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales 2021-2026 (Tons)
Figure 46. Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue 2021-2026 ($ millions)
Figure 47. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales 2021-2026 (Tons)
Figure 48. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue 2021-2026 ($ millions)
Figure 49. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country in 2025
Figure 50. Americas High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Country (2021-2026)
Figure 51. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Figure 52. Americas High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Application (2021-2026)
Figure 53. United States High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 54. Canada High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 55. Mexico High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 56. Brazil High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 57. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Region in 2025
Figure 58. APAC High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Region (2021-2026)
Figure 59. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Figure 60. APAC High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Application (2021-2026)
Figure 61. China High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 62. Japan High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 63. South Korea High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 64. Southeast Asia High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 65. India High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 66. Australia High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 67. China Taiwan High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 68. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country in 2025
Figure 69. Europe High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share by Country (2021-2026)
Figure 70. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Figure 71. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Application (2021-2026)
Figure 72. Germany High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 73. France High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 74. UK High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 75. Italy High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 76. Russia High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 77. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country (2021-2026)
Figure 78. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Type (2021-2026)
Figure 79. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Application (2021-2026)
Figure 80. Egypt High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 81. South Africa High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 82. Israel High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 83. Turkey High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 84. GCC Countries High-Purity PLGA Polymers for Long-Acting Injectables Revenue Growth 2021-2026 ($ millions)
Figure 85. Manufacturing Cost Structure Analysis of High-Purity PLGA Polymers for Long-Acting Injectables in 2026
Figure 86. Manufacturing Process Analysis of High-Purity PLGA Polymers for Long-Acting Injectables
Figure 87. Industry Chain Structure of High-Purity PLGA Polymers for Long-Acting Injectables
Figure 88. Channels of Distribution
Figure 89. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Forecast by Region (2027-2032)
Figure 90. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share Forecast by Region (2027-2032)
Figure 91. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share Forecast by Type (2027-2032)
Figure 92. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share Forecast by Type (2027-2032)
Figure 93. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share Forecast by Application (2027-2032)
Figure 94. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Market Share Forecast by Application (2027-2032)
